Neural antibodies can specifically label and recognize molecules on nerve cells, enabling a more comprehensive understanding and study of the biological properties, functions, and mechanisms of nerve cells in neurodegenerative diseases.
Covering iPSC neural cells, brain organoids, and microelectrode array services, our tools support neural development, disease modeling, and drug screening with high quality and reliable performance to meet diverse research needs.
Number of Launched Drugs:0 Number of Drugs in Clinical Trials:1 Lastest Research Phase:Phase 1 Clinical
Product Consulting
* We couldn't find what you're looking for. You can let us help by filling the form below. Our
tech team will get back to you shortly.
* This form is only used to collect product demand consultation. All the information
will be kept strictly confidential.
Glycoprotein / GP (virus) Molecule Synonym Name
Glycoprotein GP55,Envelope glycoprotein B
Glycoprotein / GP (virus) Molecule Background
EBOV encodes seven structural proteins: nucleoprotein (NP), polymerase cofactor (VP35), (VP40), GP, transcription activator (VP30), VP24, and RNA polymerase (L). GP protein contains 160-kDa envelope-attached glycoprotein (GP) and a 110 kDa secreted glycoprotein (sGP). GP is a class I fusion protein which assembles as trimers on viral surface and plays an important role in virus entry and attachment. Mature GP is a disulfide-linked heterodimer formed by two subunits, GP1 and GP2, which are generated from the proteolytical process of GP precursor (pre-GP) by cellular furin during virus assembly . GP1 is responsible for binding to the receptor(s) on target cells. Interacts with CD209/DC-SIGN and CLEC4M/DC-SIGNR which act as cofactors for virus entry into the host cell. GP2 acts as a class I viral fusion protein. GP1,2 mediates endothelial cell activation and decreases endothelial barrier function. sGP seems to possess an anti-inflammatory activity as it can reverse the barrier-decreasing effects of TNF alpha.